NasdaqGM:QTNT

Stock Analysis Report

Executive Summary

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide.

Snowflake

Fundamentals

Limited growth with worrying balance sheet.


Similar Companies

Share Price & News

How has Quotient's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.0%

QTNT

-0.003%

US Medical Equipment

1.3%

US Market


1 Year Return

4.9%

QTNT

11.9%

US Medical Equipment

5.9%

US Market

Return vs Industry: QTNT underperformed the US Medical Equipment industry which returned 11.9% over the past year.

Return vs Market: QTNT underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

QTNTIndustryMarket
7 Day-1.0%-0.003%1.3%
30 Day-17.1%-3.0%-1.9%
90 Day-30.9%-0.6%-1.8%
1 Year4.9%4.9%12.8%11.9%8.3%5.9%
3 Year-3.7%-3.7%69.6%64.5%45.6%36.2%
5 Year-23.9%-23.9%129.6%104.0%66.1%47.9%

Price Volatility Vs. Market

How volatile is Quotient's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Quotient undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Quotient is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Quotient has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Quotient forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

30.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QTNT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QTNT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QTNT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QTNT's revenue (34.6% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: QTNT's revenue (34.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if QTNT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Quotient performed over the past 5 years?

-22.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: QTNT is unprofitable, and losses have increased over the past 5 years at a rate of -22.5% per year.

Accelerating Growth: Unable to compare QTNT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QTNT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: QTNT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: QTNT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: QTNT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Quotient's financial position?


Financial Position Analysis

Short Term Liabilities: QTNT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: QTNT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: QTNT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: QTNT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: QTNT has a high level of physical assets or inventory.

Debt Coverage by Assets: QTNT has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QTNT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: QTNT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.8% each year


Next Steps

Dividend

What is Quotient's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate QTNT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate QTNT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if QTNT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QTNT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QTNT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Quotient's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Franz Walt (60yo)

1.5yrs

Tenure

US$4,141,834

Compensation

Mr. Franz Walt has been Chief Executive Officer of Quotient Limited since April 2018 and served as its Interim Chief Executive Officer from March 21, 2018 to April 2018. He has been Director at Quotient Li ...


CEO Compensation Analysis

Compensation vs. Market: Franz has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Franz's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

0.8yrs

Average Tenure

60yo

Average Age

Experienced Management: QTNT's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

6.8yrs

Average Tenure

68yo

Average Age

Experienced Board: QTNT's board of directors are considered experienced (6.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$27,40517 Jun 19
Frederick Hallsworth
EntityIndividual
Role
Member of the Board of Directors
Director
Shares3,150
Max PriceUS$8.70
BuyUS$65,00012 Dec 18
Frederick Hallsworth
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$6.50
BuyUS$13,000,00010 Dec 18
Perceptive Advisors LLC
EntityCompany
Shares2,000,000
Max PriceUS$6.50

Ownership Breakdown


Management Team

  • Chris Lindop (61yo)

    Chief Financial Officer

    • Tenure: 0yrs
    • Compensation: US$1.54m
  • Roland Boyd (63yo)

    Group Financial Controller & Treasurer

    • Tenure: 0yrs
    • Compensation: US$379.85k
  • Jeremy Stackawitz (44yo)

    President of Commercial & Reagent

    • Tenure: 0.8yrs
    • Compensation: US$947.45k
  • Ed Farrell (49yo)

    President of R&D and Manufacturing

    • Tenure: 0.8yrs
    • Compensation: US$995.40k
  • Franz Walt (60yo)

    CEO & Director

    • Tenure: 1.5yrs
    • Compensation: US$4.14m

Board Members

  • Zubeen Shroff (54yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$165.19k
  • Tom Bologna (71yo)

    Director

    • Tenure: 7.7yrs
    • Compensation: US$201.61k
  • Sarah O'Connor (59yo)

    Director

    • Tenure: 5.3yrs
    • Compensation: US$207.86k
  • L. John Wilkerson (76yo)

    Director

    • Tenure: 7.7yrs
    • Compensation: US$145.11k
  • Heino von Prondzynski (70yo)

    Chairman of the Board

    • Tenure: 1.6yrs
    • Compensation: US$517.28k
  • Fred Hallsworth (66yo)

    Director

    • Tenure: 8.7yrs
    • Compensation: US$210.69k
  • Brian McDonough (72yo)

    Director

    • Tenure: 7.4yrs
    • Compensation: US$205.11k
  • Franz Walt (60yo)

    CEO & Director

    • Tenure: 1.5yrs
    • Compensation: US$4.14m

Company Information

Quotient Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quotient Limited
  • Ticker: QTNT
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$481.779m
  • Shares outstanding: 66.27m
  • Website: https://quotientbd.com

Number of Employees


Location

  • Quotient Limited
  • B1, Business Park Terre Bonne
  • Route de Crassier 13
  • Eysins
  • Vaud
  • 1262
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QTNTNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDMay 2014
U4WDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2014

Biography

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. T ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:17
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.